# Mike Nohaile

> Mike Nohaile is the CEO of Prellis Biologics, a Berkeley biotech using two-photon holographic 3D bioprinting to grow lymph node organoids and pull antibody candidates straight from the human immune repertoire. A molecular biologist by training (PhD from UC Berkeley, postdoc at MIT), he spent decades operating at the top of the pharma industry - partner at McKinsey, Global Head of Molecular Diagnostics at Novartis, Senior VP of Strategy, Commercialization & Innovation at Amgen, and Chief Scientific Officer at Generate Biomedicines - before taking the helm at Prellis in 2022 alongside a $35M Series C. He is a vocal skeptic of AI drug-discovery hype, insisting AI optimizes proteins but does not yet invent medicines.

- **Role:** Chief Executive Officer at Prellis Biologics
- **Organizations:** Prellis Biologics, Generate Biomedicines, Amgen, Novartis, McKinsey & Company
- **Nationality:** American
- **Education:** PhD, Molecular and Cell Biology, University of California, Berkeley, Postdoctoral Fellow, Department of Biology, Massachusetts Institute of Technology (MIT)
- **Known for:** Led corporate strategy, portfolio management, commercialization, and all data/digital health/AI efforts at Amgen as a member of the executive committee, Served as Chief Scientific Officer at Generate Biomedicines, a Flagship Pioneering company at the frontier of generative biology, Took the helm of Prellis Biologics and closed a $35M Series C co-led by Celesta Capital and Avidity Partners

## Career timeline

- **Early career** — Partner at McKinsey & Company (New Jersey office), focused on healthcare - diagnostics, devices, pharmaceuticals
- **Novartis era** — Global Head of Molecular Diagnostics at Novartis in Switzerland; also held corporate and pharmaceutical strategy roles
- **2012** — Joined Amgen as Vice President of Strategy (December)
- **2017** — Promoted to Senior VP of Strategy, Commercialization & Innovation at Amgen; joined executive committee and led data, digital health, and AI efforts
- **2021-2022** — Chief Scientific Officer at Generate Biomedicines (Flagship); featured on Amgen's 'Generative Biology Revolution' podcast
- **2022** — Appointed CEO of Prellis Biologics; company raised $35M Series C (announced August 10, 2022), bringing total funding to $64.5M

## Achievements

- Led corporate strategy, portfolio management, commercialization, and all data/digital health/AI efforts at Amgen as a member of the executive committee
- Served as Chief Scientific Officer at Generate Biomedicines, a Flagship Pioneering company at the frontier of generative biology
- Took the helm of Prellis Biologics and closed a $35M Series C co-led by Celesta Capital and Avidity Partners
- Built a career spanning consulting (McKinsey), diagnostics (Novartis), big pharma (Amgen), and AI-native biotech (Generate)

## Latest updates

- **2022-08** — Named CEO of Prellis Biologics as the company raised a $35M Series C and founder Melanie Matheu moved to CTO.

## Links

- Website: https://prellisbio.com
- LinkedIn: https://www.linkedin.com/in/mike-nohaile/
- Twitter/X: https://twitter.com/prellisbio
- Facebook: https://facebook.com/PrellisBio/

---

Profile page: https://yespress.io/mike-nohaile
Published by YesPress — https://yespress.io
Last updated: 2026-06-10